Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
ImmunoPrecise Antibodies Ltd (IPA) delivers cutting-edge antibody solutions through AI-enhanced multi-omics modeling and proprietary biotechnologies. This news hub provides investors and researchers with essential updates on corporate developments, scientific breakthroughs, and strategic partnerships driving innovation in therapeutic antibody discovery.
Access timely reports on IPA's R&D milestones, regulatory progress, and technology advancements. Our curated collection features press releases covering key areas including patent filings, collaborative research initiatives, and platform enhancements within the antibody development lifecycle.
Stay informed about IPA's role in advancing precision immunology through updates on their custom antibody services, AI-driven discovery platforms, and client-focused solutions for pharmaceutical and academic partners. Bookmark this page for direct access to verified corporate communications and scientific progress reports.
ImmunoPrecise Antibodies (IPA) has entered into a $3.0 million convertible debenture agreement with Yorkville Advisors Global, LP. The deal includes two tranches: $2.0 million completed on July 16, 2024, and $1.0 million pending SEC approval. Key features:
- 8.0% annual interest rate
- Convertible to common shares at the lower of $1.16 or 95% of the lowest 10-day VWAP
- Redeemable if stock price is below $1.16
- Monthly payments required if stock price falls below $0.20
- Conversion to $300,000 per 30-day period if price is below $1.16
Proceeds will be used for R&D, capital expenditures, and working capital. Clear Street acted as placement agent.
ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research and technology company, has announced it will release its financial results and business highlights for the fourth quarter and fiscal year 2024 on July 25th, 2024. The company will host an earnings conference call via webcast at 10:30 AM Eastern Time on the same day.
Investors can access the live audio webcast through a link on IPA's Investor Relations website. A replay will be available after the call. Participants can join the conference call using provided toll-free and international dial-in numbers, using the Conference ID 9236374 or Conference Name.
ImmunoPrecise Antibodies (NASDAQ: IPA) has appointed Kristin Taylor as its Chief Financial Officer, effective immediately. Taylor, who has served as Interim CFO since September 19, 2023, brings extensive experience from early-stage and large growth companies, including Bay West and B-MoGen Biotechnologies. She has a background in growth strategies, fundraising, due diligence, financial analysis, and compliance. Taylor holds an MBA from Carlson School of Management and a Bachelor of Science in Business Administration. She is also a Certified Public Accountant (inactive). The CEO of IPA, Jennifer Bath, praised Taylor's performance during her interim tenure and expressed confidence in her ability to lead the company’s financial operations.
ImmunoPrecise Antibodies (IPA) announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI to develop an AI model for pharmacogenomics, leveraging BioStrand's LENSai technology. This partnership aims to enhance precision medicine by integrating AI with vast genomic data to improve patient outcomes and optimize drug therapies. The collaboration aligns with IPA's goal to advance tailored therapies and improve healthcare solutions. The LENSai API, recently made available to select partners, will be expanded through this initiative. The model could revolutionize the $400 billion prescription drug market, presenting a significant investment opportunity.
ImmunoPrecise Antibodies' subsidiary, BioStrand, received the prestigious 2024 Impact Award by InterSystems for its LENSai technology. Selected from over 1,000 projects, LENSai was recognized for advancing biotherapeutic research, introducing novel methods, and setting industry benchmarks. The award was presented at InterSystems' Global Summit, attracting over 1,200 industry leaders globally. Dr. Jennifer Bath, CEO of ImmunoPrecise, emphasized the award's significance in highlighting BioStrand's pioneering contributions.
ImmunoPrecise Antibodies (NASDAQ: IPA) announces the commercial release of LENSai API by its subsidiary, BioStrand. This AI-driven software integrates electronic health records to enhance drug discovery and development. The software, available immediately, will be showcased at the InterSystems Global Summit 2024. LENSai API is designed to address industry pain points by combining BioStrand’s patented technology with extensive datasets. It is expected to boost commercialization via partnerships and a subscription model. Future developments include a full LENSai data management platform, slated for Q1/Q2 2025.
IPA's subsidiary, BioStrand, announced the application of their Foundation AI Model, LENSai, leveraging advanced Large Language Models (LLM) to analyze Electronic Health Records (EHR). This integration enhances the use of real-world data in drug discovery and precision medicine development. EHRs, now a critical commodity, are being optimized by BioStrand to offer superior insights and drive innovation. The model's effectiveness will be demonstrated by Head of Technology Dirk Van Hyfte at the InterSystems Global Summit 2024.
FAQ
What is the current stock price of Immunoprecise (IPA)?
What is the market cap of Immunoprecise (IPA)?
